Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. (Nasdaq: ALT) generates a steady flow of news as a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver, metabolic and cardiometabolic diseases. Most company updates center on its lead investigational medicine, pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), alcohol-associated liver disease (ALD) and obesity.
News coverage of ALT frequently highlights clinical trial milestones. Altimmune issues detailed press releases on the IMPACT Phase 2b trial in MASH, including 24-week and 48-week topline data, changes in non-invasive tests of fibrosis and hepatic inflammation, and AI-based digital pathology analyses of liver biopsies. Additional updates describe progress in the RECLAIM Phase 2 trial in AUD and the RESTORE Phase 2 trial in ALD, including enrollment status and expected timelines for topline results.
Investors and followers of ALT stock also see regulatory and scientific news, such as Fast Track designations for pemvidutide in MASH and AUD, Breakthrough Therapy Designation for MASH, and publication of IMPACT trial data in peer-reviewed journals. Presentations at major medical meetings, including late-breaking oral and poster sessions at The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD), are common subjects of company announcements.
Altimmune’s news flow further includes corporate and financial updates. These range from quarterly financial results and business updates to CEO succession plans, executive appointments, term loan amendments and at-the-market equity offering arrangements disclosed in SEC filings and companion press releases. For anyone tracking ALT, this news page brings together clinical, regulatory, scientific and corporate developments in one place, making it easier to follow how Altimmune’s programs and capital strategy evolve over time.
Altimmune (Nasdaq: ALT) reported AI-based digital pathology analysis from the IMPACT Phase 2b pemvidutide trial in MASH showing significant fibrosis reductions vs placebo at 24 weeks.
Key results: 31% of patients on pemvidutide 1.8 mg achieved ≥60% total fibrosis area reduction (n=85) vs 8% placebo (n=86; p=0.0003); early fibrosis ≥60% reduction: 34% (1.8 mg) vs 9% placebo (p<0.0001); advanced fibrosis ≥60% reduction: 27% (1.8 mg) vs 11% placebo (p=0.0063). Non-invasive tests including PRO-C3:CTX-III ratio and PRO-C6 also improved.
Altimmune (Nasdaq: ALT) reported Q3 2025 corporate and financial updates on November 6, 2025. Key points: $210.8M cash, cash equivalents and short-term investments as of September 30, 2025 (about +60% vs. Dec 31, 2024); net loss of $19.0M (−$0.21 per share) for Q3 2025; R&D expense of $15.0M in Q3 2025. Important clinical milestones: an End-of-Phase 2 meeting with FDA scheduled Q4 2025 for pemvidutide MASH and 48-week IMPACT data expected before year-end 2025. Corporate: amended Hercules facility to $125M with an additional $20M draw, and three senior hires (CMO, CCO, CLO).
Altimmune (Nasdaq: ALT) said company management will attend two investor conferences in November 2025: a Stifel 2025 Healthcare Conference fireside chat on November 12, 2025 at 10:00 a.m. ET, and a Jefferies Global Healthcare Conference fireside chat on November 20, 2025 at 9:30 a.m. GMT. Management will be available for one-on-one meetings. Both sessions will be webcast and accessible via the Events section of the company's website.
Altimmune (Nasdaq: ALT) announced early completion of enrollment in RECLAIM, a Phase 2 trial of pemvidutide in adults with alcohol use disorder (AUD). Approximately 100 patients were randomized 1:1 to 2.4 mg pemvidutide or placebo once weekly for 24 weeks. The primary endpoint is change in average number of heavy drinking days per week; key secondary endpoints include a 2-level WHO risk drinking reduction and change in PEth biomarker. Enrollment finished several months ahead of schedule and topline results are expected in 2026. Altimmune is also enrolling the RESTORE Phase 2 ALD trial and expects 48-week IMPACT results for MASH later this quarter.
Altimmune (Nasdaq: ALT) will report its third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. ET the same day to discuss results and provide a business update.
The live webcast will be available on Altimmune’s Investor Relations website and requires registration to receive dial-in numbers and a unique PIN. A replay of the call will be posted on the Investor Relations site and remain available for up to three months.
Altimmune (Nasdaq: ALT) will present 24-week Phase 2b IMPACT data for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) at AASLD The Liver Meeting® 2025 in Washington, D.C., Nov 7–11, 2025.
Two late-breaking presentations are scheduled: an oral podium on Nov 11, 2025 at 11:45 a.m. ET by Dr. Mazen Noureddin covering the randomized, placebo-controlled trial (publication 5001), and a late-breaking poster on Nov 8, 2025 from 1:00–2:00 p.m. ET by Dr. Julio Gutierrez showing AI-based digital pathology analysis of liver fibrosis (publication 5025). The company expects to announce 48-week data in Q4 2025 and will post the presentation and poster on its Events page.
Altimmune (NASDAQ:ALT) has appointed Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels brings over 30 years of experience and will lead the clinical development of pemvidutide, including the planned Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH).
He succeeds Scott Harris, M.D., who will remain as Senior Strategic Advisor until February 2026. Dr. Arbet-Engels joins from X4 Pharmaceuticals, where he contributed to the successful approval of Xolremdi. His compensation package includes options to purchase 450,000 shares and 150,000 restricted stock units of Altimmune's common stock.
The appointment comes at a crucial time as Altimmune prepares for upcoming 48-week data from the IMPACT trial in MASH and ongoing Phase 2 trials in Alcohol Use Disorder and Alcohol-associated Liver Disease.Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences. Management will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 10:30 a.m. ET, and the H.C. Wainwright Liver Disease Virtual Conference on October 21, 2025, at 7:00 a.m. ET.
Both presentations will feature fireside chats and will be available via webcast through the Events section of Altimmune's website. The company's management team will also be available for one-on-one meetings with investors during these events.
Altimmune (NASDAQ:ALT) has appointed Linda M. Richardson as Chief Commercial Officer, effective September 16, 2025. Richardson brings over 30 years of experience in sales, marketing, and commercial development, with expertise in metabolic disease, hepatology, cardiovascular, and addiction medicine.
Richardson joins Altimmune as the company approaches Phase 3 development of pemvidutide in MASH. She previously served as Chief Commercial Officer at Intercept Pharmaceuticals until early 2024 and held senior positions at Chimerix, Sanofi, Reliant Pharmaceuticals, and GSK.
As part of her compensation package, Richardson will receive options to purchase 278,000 shares and 96,000 restricted stock units (RSUs), with a four-year vesting schedule.
Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on peptide-based therapeutics for liver and cardiometabolic diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will attend the Wells Fargo Healthcare Conference in Boston on September 5 for one-on-one meetings, the H.C. Wainwright Global Investment Conference in New York on September 9 with a fireside chat at 8:30 a.m. ET, and the Morgan Stanley Global Healthcare Conference in New York on September 10 with a fireside chat at 7:45 a.m. ET. The fireside chat sessions will be available via webcast on Altimmune's website.